Pernix Therapeutics Holdings

Eton Pharmaceuticals to Report Second Quarter Financial Results on Wednesday, August 12, 2020

Tuesday, August 4, 2020 - 9:10pm

DEER PARK, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wednesday, August 12, 2020.

Key Points: 
  • DEER PARK, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wednesday, August 12, 2020.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products.
  • The company has an additional seven products under development, including five that are under review with the FDA.

ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer

Monday, August 3, 2020 - 11:50am

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani has been named the Companys President and Chief Executive Officer, effective September 8, 2020.

Key Points: 
  • ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani has been named the Companys President and Chief Executive Officer, effective September 8, 2020.
  • With his proven ability to create high-growth cultures and deliver financial results, together with his operational experience in both generics and specialty pharmaceuticals, Nikhil is an ideal choice to lead our next phase of growth and to achieve our corporate objectives, stated Patrick Walsh, Interim President and Chief Executive Officer of ANI Pharmaceuticals.
  • Mr. Lalwani is a proven executive who brings over 20 years of pharmaceutical and healthcare industry experience to ANI.
  • ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Novus Therapeutics Reports First Quarter 2020 Financial Results

Friday, May 15, 2020 - 11:30am

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020.
  • The company had $11.8 million in cash and cash equivalents as of March 31, 2020.
  • Research and development (R&D) expenses were $1.6 million for the three months ended March 31, 2020, compared to $3.0 million for the same period in 2019.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat.

Eton Pharmaceuticals to Report First Quarter Financial Results on Thursday, May 14, 2020

Wednesday, May 6, 2020 - 9:30pm

DEER PARK, Ill., May 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May 14, 2020.

Key Points: 
  • DEER PARK, Ill., May 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May 14, 2020.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products.
  • The company has an additional eight products under development, including three that are under review with the FDA.

Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results

Tuesday, March 17, 2020 - 11:30am

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the fourth quarter and full-year ended December 31, 2019.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the fourth quarter and full-year ended December 31, 2019.
  • Research and development (R&D) expenses were $1.3 million for the three months ended December 31, 2019, compared to $2.7 million for the same period in 2018.
  • R&D expenses were $8.1 million for the year ended December 31, 2019, compared to $6.8 million for the same period in 2018.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat.

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020

Thursday, February 27, 2020 - 9:10pm

DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, March 5, 2020.

Key Points: 
  • DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, March 5, 2020.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products.
  • The companys first commercial product, Biorphen, is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019.

Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference

Thursday, February 13, 2020 - 9:05pm

DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Tuesday, February 25, 2020 in New York, NY.

Key Points: 
  • DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Tuesday, February 25, 2020 in New York, NY.
  • Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products.
  • Eton is primarily focused on hospital injectable and pediatric oral liquid products.
  • The company has an additional eight products under development, including three that are under review with the FDA.

Novus Therapeutics Reports Third Quarter 2019 Financial Results

Wednesday, November 13, 2019 - 12:30pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.
  • We expect results from this study to be available in the first half of 2020.
  • Research and development (R&D) expenses were $1.5 million for the three months ended September 30, 2019, compared to $1.7 million for the same period in 2018.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

Wednesday, November 6, 2019 - 9:05pm

DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday, November 14, 2019.

Key Points: 
  • DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday, November 14, 2019.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 1416459.
  • Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing the FDAs 505(b)(2) regulatory pathway.

OnKure Expands Executive Team and Appoints Head of Discovery, Chief Financial Officer and General Counsel

Tuesday, September 24, 2019 - 2:00pm

I am excited to join the OnKure team, a very experienced group with a history of discovering and developing great molecules, said Dr. Winkler.

Key Points: 
  • I am excited to join the OnKure team, a very experienced group with a history of discovering and developing great molecules, said Dr. Winkler.
  • He has over 25 years of executive-level financial expertise, including serving as the Chief Financial Officer for three publicly-traded pharmaceutical companies.
  • Mr. Carruthers joins OnKure from Nivalis Therapeutics (Nasdaq: NVLS), where he served as Interim President, Chief Financial Officer and Secretary.
  • All the new management team members will report directly to Tony Piscopio, Ph.D., OnKures Chief Executive Office and President.